STOCKHOLM, Sweden, June 17, 2003 (PRIMEZONE) -- The Swedish tradition of drug discovery and development is one of the strongest in the world. Following the growth of Pharmacia and AstraZeneca into global pharma companies, a new breed of companies is emerging. A number of the most successful companies will offer their research and technology to new partners, clients and investors at the BIO2003 Annual Convention and Exhibition in Washington, June 22-25.
Active Biotech
Active Biotech (Other OTC:ACTBF) is seeking partnerships for a novel oral immunomodulatory drug (SAIK-MS) aimed at the treatment of multiple sclerosis, as well as for an oral drug (TASQ) designed for the treatment of prostate cancer. The company is also seeking collaboration partners in relation to a novel concept (TTS) for immunotherapy of cancer. cecilia.hofvander@activebiotech.com
Affibody
Seeking partnerships with pharmaceutical companies for target identification and validation using Affibody's proprietary technology. Marten.osterlund@affibody.com
Bioventia
Bioventia is acting as a link between innovations, financing and competent management and is currently looking for international strategic partnerships. lena.lebel@bioventia.com
Biovitrum
Biovitrum is actively looking for in-licensing partners to strengthen the project portfolio in our core therapeutic areas: type 2 diabetes, obesity and oncology. Biovitrum also has expert knowledge and capabilities in process development and GMP manufacturing of recombinant protein drugs, which is offered to Biovitrum's partners and customers. lars.bjork@biovitrum.com
Global Genomics
Introducing Tangerine, a solution for gene expression profiling that identifies virtually all active genes in a given sample. The technology can be applied within drug discovery to support target and lead identification and validation through to analysis during clinical trials. ulf@globalgenomics.com
Karo Bio
Product opportunities are Selective GR modulators/ Anti-inflammatory therapeutics, Selective AR modulators/ Prostate cancer, Selective TR modulators, HRT, SERMs, Dxr compound series/ Antibacterial, IspB compound series/ Antibacterial, 10 Biokey(R) assays/ Antibacterial. lars.ohman@karobio.se
Melacure Therapeutics
Seeking partnerships with leading companies in therapeutic areas relevant to the melanocortin receptor field (MC1, MC3, MC4 and MC5) with opportunities in inflammation, obesity, diabetes and sexual dysfunction. ulf.vallgren@melacure.com
NeuroNova
NeuroNova is seeking strategic partnerships with pharmaceutical and biotechnology companies with an international presence in order to further the clinical development and commercialisation of its innovative therapies within its Therapeutic Neurogenesis and its Cell Transplantation Therapy programs. johan.haggblad@neuronova.com
Other Swedish organizations also represented at BIO2003 are:
Invest in Sweden Agency: www.isa.se Karolinska Institute: www.ki.se Biotech Forum: www.biotechforum.org Stockholm Uppsala Bioregion: www.stockholmuppsalabioregion.com Swedish Agency for Innovation Systems: www.vinnova.se Swedish Trade Council: www.swedishtrade.com UppsalaBIO: www.investin.uppsala.se
For more information on Swedish Biotechnology, see www.biosweden.org.
For more information, contact: Mr. David Ernstsson, Director Swedish Bioscience Programme, Swedish Trade Council, Cell: +46 708 85 87 01, E-mail: david.ernstsson@swedishtrade.se, Ms Clare Hobby, Swedish Bioscience Programme, Swedish Trade Council / Los Angeles, Cell: +1 312 925 6560, E-mail: clare.hobby@swedishtrade.se
The press release in PDF format can be downloaded from the following link.